TAIPEI, Oct. 6, 2025 -- The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), an organization focused on fostering Taiwan's biotech ecosystem, announced today that it will lead a delegation of 16 biotech industry partners from Taiwan to participate in BioJapan 2025 (Yokohama, October 8-10, 2025). Taiwan's participation in BioJapan 2025, through the Taiwan Pavilion and delegation, will serve as an impactful forum to showcase the value that Taiwan's ecosystem can bring to Japanese companies in jointly realizing the future of biotech innovation.

BPIPO's Participation Details at BioJapan 2025

• Booth Number: B-77 (Taiwan Pavilion)
• Dates: October 8 to 10, 2025, at PACIFICO Yokohama, Yokohama, Japan
• "Cheers & Collab" Gathering: October 9, from 4pm to 5pm at the Taiwan Pavilion, featuring drinks and snacks

At the event, BPIPO will showcase Taiwan's cutting-edge competitiveness in high-growth sectors, including regenerative medicine, AI healthcare, precision health, and contract development and manufacturing (CDMOs). Taiwan's biotech ecosystem offers a unique blend of capabilities, including:

• Advanced manufacturing
• Regenerative medicine expertise
• Robust integration of information and communications technology (ICT)
• Pro-growth regulatory framework aligned with international standards

Taiwanese Biotech Companies Advance in Japan

With these capabilities, Taiwanese companies continue to flourish in Japan. In 2024, Japan's CBC became an official distributor for Taiwan's TBMC, allowing the company to expand its presence in the Japanese market. In addition, Leeuwenhoek successfully launched its Flora Le Light Synbiotic in Japan.

This year, Amaran Biotech established a strategic partnership with Nippon Fine Chemical to jointly enhance CDMO manufacturing technology services for nanoparticle-based drugs in Taiwan and Japan. Taiwan-Japan collaborations have also yielded a slew of developments: AM Biotech's high-purity targeted exosomes were officially registered with the Japan Cosmetic Industry Association, and its ExoGiov exosomes have expanded from cosmetics to regenerative medicine. Another Taiwanese company, LumiSTAR, has been selected for Takeda Pharmaceutical's COCKPI-T® program to advance innovation in drug discovery and development.

Following the recent securing of Foreign Manufacturer Accreditation from the Japanese government, Steminent aims to achieve certification in 2026 for its new regenerative medicine, Stemchymal®. As a testament to growing collaboration, one of the delegation members, Creative Life Science, and Japan's Myoridge will sign an MOU, combining strengths in cell culture and production channels to unleash new possibilities for regenerative medicine.

The Taiwan delegation will also visit Astellas Pharma, a leading Japanese multinational pharmaceutical company, to tour its innovative SakuLab facility and to foster collaboration in cell therapy and bioprocessing.

Below is the complete delegation list:

For more information, please visit https://ccd.nat.gov.tw/biopharm.

Media Enquiries:

Janet Chung
cjchung@biopharm.org.tw